New data confirm pharmacological effect of Leqembi, says Eisai
Japanese drugmaker Eisai (TYO: 4523) and US biotech Biogen (Nasdaq: BIIB) announced new data confirming the pharmacological effect of Leqembi (lecanemab) were presented at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference.
The findings represent the results from a large-scale clinical study demonstrating, for the first time, that binding of lecanemab to PF can be measured in CSF, enabling further understanding of how lecanemab slows Alzheimer’s disease (AD) progression.
In a CSF sub-cohort (n=410) of the Phase III Clarity AD study, total PF concentration in CSF was quantified using an ultrasensitive assay. Changes from baseline (pre-treatment) for the placebo group (natural course) and the lecanemab group were compared, and associations between PF changes and neurodegeneration biomarkers were analyzed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze